<?xml version='1.0' encoding='utf-8'?>
<document id="28424965"><sentence text="Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer."><entity charOffset="54-63" id="DDI-PubMed.28424965.s1.e0" text="ceritinib" /></sentence><sentence text="The impact of proton pump inhibitors (PPIs) on the pharmacokinetics (PK) and efficacy of ceritinib was evaluated"><entity charOffset="89-98" id="DDI-PubMed.28424965.s2.e0" text="ceritinib" /></sentence><sentence text="" /><sentence text="A healthy subject drug-drug interaction (DDI) study was conducted to assess the effect of esomeprazole on the PK of a single 750 mg dose of ceritinib"><entity charOffset="90-102" id="DDI-PubMed.28424965.s4.e0" text="esomeprazole" /><entity charOffset="140-149" id="DDI-PubMed.28424965.s4.e1" text="ceritinib" /><pair ddi="false" e1="DDI-PubMed.28424965.s4.e0" e2="DDI-PubMed.28424965.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28424965.s4.e0" e2="DDI-PubMed.28424965.s4.e1" /></sentence><sentence text=" To further investigate the impact of PPIs on the PK and efficacy of ceritinib in ALK-positive cancer patients, two subgroup analyses were performed"><entity charOffset="69-78" id="DDI-PubMed.28424965.s5.e0" text="ceritinib" /></sentence><sentence text=" Analysis 1 evaluated ceritinib steady-state trough concentration (Ctrough,ss) and overall response rate (ORR) by concomitant use of PPIs in patients from the ASCEND-1, -2, and -3 studies; analysis 2 evaluated ceritinib single-dose and steady-state AUC0-24h and C max by concomitant PPI use in patients from ASCEND-1 using a definition of PPI usage similar to that used in the healthy subject study"><entity charOffset="22-31" id="DDI-PubMed.28424965.s6.e0" text="ceritinib" /><entity charOffset="210-219" id="DDI-PubMed.28424965.s6.e1" text="ceritinib" /><pair ddi="false" e1="DDI-PubMed.28424965.s6.e0" e2="DDI-PubMed.28424965.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28424965.s6.e0" e2="DDI-PubMed.28424965.s6.e1" /></sentence><sentence text="" /><sentence text="In the healthy subject study, co-administration of a single 750 mg dose of ceritinib with esomeprazole 40 mg for 6 days decreased ceritinib AUC0-∞ by 76% and C max by 79%"><entity charOffset="75-84" id="DDI-PubMed.28424965.s8.e0" text="ceritinib" /><entity charOffset="90-102" id="DDI-PubMed.28424965.s8.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.28424965.s8.e0" e2="DDI-PubMed.28424965.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28424965.s8.e0" e2="DDI-PubMed.28424965.s8.e1" /></sentence><sentence text=" However, based on subgroup analysis 1, patients had similar C trough,ss and ORR regardless of concomitant PPI usage" /><sentence text=" Based on analysis 2, co-administration of a single 750 mg ceritinib dose with PPIs for 6 days in patients suggested less effect on ceritinib exposure than that observed in healthy subjects as AUC0-24h decreased by 30% and C max decreased by 25%"><entity charOffset="59-68" id="DDI-PubMed.28424965.s10.e0" text="ceritinib" /><entity charOffset="132-141" id="DDI-PubMed.28424965.s10.e1" text="ceritinib" /><pair ddi="false" e1="DDI-PubMed.28424965.s10.e0" e2="DDI-PubMed.28424965.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28424965.s10.e0" e2="DDI-PubMed.28424965.s10.e1" /></sentence><sentence text=" No clinically meaningful effect on steady-state exposure was observed after daily dosing" /><sentence text="" /><sentence text="Long-term administration of ceritinib with PPIs does not adversely affect the PK and efficacy of ceritinib in ALK-positive cancer patients"><entity charOffset="28-37" id="DDI-PubMed.28424965.s13.e0" text="ceritinib" /><entity charOffset="97-106" id="DDI-PubMed.28424965.s13.e1" text="ceritinib" /><pair ddi="false" e1="DDI-PubMed.28424965.s13.e0" e2="DDI-PubMed.28424965.s13.e0" /><pair ddi="true" e1="DDI-PubMed.28424965.s13.e0" e2="DDI-PubMed.28424965.s13.e1" /></sentence><sentence text="" /></document>